PMC:7402624 / 3446-3688
Annnotations
LitCovid-PD-FMA-UBERON
{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T26","span":{"begin":38,"end":41},"obj":"Body_part"},{"id":"T27","span":{"begin":58,"end":61},"obj":"Body_part"}],"attributes":[{"id":"A26","pred":"fma_id","subj":"T26","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A27","pred":"fma_id","subj":"T27","obj":"http://purl.org/sig/ont/fma/fma62874"}],"text":"patients maintain high Spike-specific IgG titers (6, 26). IgA levels also can remain high and may correlate with disease severity (25, 27). Furthermore, neutralizing antibodies can control SARS-CoV2 infection in vitro and in vivo (4, 28, 29)."}
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"88","span":{"begin":0,"end":8},"obj":"Species"},{"id":"89","span":{"begin":189,"end":198},"obj":"Species"},{"id":"93","span":{"begin":199,"end":208},"obj":"Disease"}],"attributes":[{"id":"A88","pred":"tao:has_database_id","subj":"88","obj":"Tax:9606"},{"id":"A89","pred":"tao:has_database_id","subj":"89","obj":"Tax:2697049"},{"id":"A93","pred":"tao:has_database_id","subj":"93","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"patients maintain high Spike-specific IgG titers (6, 26). IgA levels also can remain high and may correlate with disease severity (25, 27). Furthermore, neutralizing antibodies can control SARS-CoV2 infection in vitro and in vivo (4, 28, 29)."}
LitCovid-PD-MONDO
{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T27","span":{"begin":189,"end":193},"obj":"Disease"},{"id":"T28","span":{"begin":199,"end":208},"obj":"Disease"}],"attributes":[{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"patients maintain high Spike-specific IgG titers (6, 26). IgA levels also can remain high and may correlate with disease severity (25, 27). Furthermore, neutralizing antibodies can control SARS-CoV2 infection in vitro and in vivo (4, 28, 29)."}
LitCovid-PD-CLO
{"project":"LitCovid-PD-CLO","denotations":[{"id":"T44","span":{"begin":135,"end":137},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"}],"text":"patients maintain high Spike-specific IgG titers (6, 26). IgA levels also can remain high and may correlate with disease severity (25, 27). Furthermore, neutralizing antibodies can control SARS-CoV2 infection in vitro and in vivo (4, 28, 29)."}
LitCovid-sentences
{"project":"LitCovid-sentences","denotations":[{"id":"T26","span":{"begin":58,"end":139},"obj":"Sentence"},{"id":"T27","span":{"begin":140,"end":242},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"patients maintain high Spike-specific IgG titers (6, 26). IgA levels also can remain high and may correlate with disease severity (25, 27). Furthermore, neutralizing antibodies can control SARS-CoV2 infection in vitro and in vivo (4, 28, 29)."}